Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page




    Early clinical characteristics of Covid-19 MESHD: scoping review

    Authors: Lakshmi Manoharan; Jonathan W S Cattrall; Carlyn Harris; Katherine Newell; Blake Thomson; Mark G Pritchard; Peter G Bannister; Louise Sigfrid; Tom Solomon; Peter W Horby; Gail Carson; Piero L Olliaro

    doi:10.1101/2020.07.31.20165738 Date: 2020-08-04 Source: medRxiv

    ABSTRACT Background: The Coronavirus disease 2019 MESHD ( covid-19 MESHD) pandemic has spread rapidly across the globe. Accurate clinical characterisation studies are essential to informing research, diagnosis and clinical management efforts, particularly early in a pandemic. In this scoping review we identify the clinical characteristics of patients admitted to hospital in the early months of the pandemic, focusing on symptoms, laboratory and imaging findings, and clinical outcomes. Methods: A scoping review. MEDLINE, EMBASE and Global Health databases were searched studies published from January 1st 2020 to April 28th 2020. Studies which reported on at least 100 hospitalised patients with covid-19 MESHD of any age were included. Results: Of 1,249 studies identified through the search 78 studies were eligible for inclusion; one randomized control trial and 77 observational studies presenting data on 77,443 patients admitted with covid-19 MESHD. Most studies were conducted in China (82%), 9% in the US and 10% in Europe and two studies were set in more than one country. No studies included patients from low and middle income countries. Coagulopathy MESHD was underrecognised as a complication in the early months of the pandemic. Use of corticosteroids varied widely, and the use of anticoagulants was reported in only one study. Fever MESHD, cough and dyspnoea MESHD are less common in older adults; gastrointestinal symptoms, as the only presenting feature may be underrecognised. The most common laboratory finding was lymphocytopenia MESHD. Inflammatory biomarkers were commonly elevated, including C-reactive protein HGNC and interleukin-6 HGNC. Typical computed tomography findings include bilateral infiltrates however imaging may be normal in early disease. Data on clinical characteristics in children and vulnerable populations were limited. Conclusions: Clinical characterisation studies from early in the pandemic indicated that covid-19 MESHD is a multisystem disease MESHD, with biomarkers indicating inflammation MESHD and coagulopathy MESHD. However, early data collection on symptoms and clinical outcomes did not consistently reflect this wide spectrum. Corticosteroid use varied widely, and anticoagulants were rarely used. Clinicians should remain vigilant to the possibility of covid-19 MESHD in patients presenting without fever MESHD, cough and dyspnoea MESHD, particularly in older adults. Further characterisation studies in different at-risk populations is needed. Review registration: Available at https:// osf HGNC.io/r2ch9 Keywords: Covid-19 MESHD, clinical characteristics, symptoms, biochemical parameters, imaging, outcomes, pandemic research

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.